{
  "@context": {
    "biotools": "https://bio.tools/ontology/",
    "brick": "https://brickschema.org/schema/Brick#",
    "bsc": "http://bioschemas.org/",
    "bsct": "http://bioschemas.org/types/",
    "csvw": "http://www.w3.org/ns/csvw#",
    "dc": "http://purl.org/dc/elements/1.1/",
    "dcam": "http://purl.org/dc/dcam/",
    "dcat": "http://www.w3.org/ns/dcat#",
    "dcmitype": "http://purl.org/dc/dcmitype/",
    "dcterms": "http://purl.org/dc/terms/",
    "doap": "http://usefulinc.com/ns/doap#",
    "edam": "http://edamontology.org/",
    "foaf": "http://xmlns.com/foaf/0.1/",
    "geo": "http://www.opengis.net/ont/geosparql#",
    "odrl": "http://www.w3.org/ns/odrl/2/",
    "org": "http://www.w3.org/ns/org#",
    "owl": "http://www.w3.org/2002/07/owl#",
    "prof": "http://www.w3.org/ns/dx/prof/",
    "prov": "http://www.w3.org/ns/prov#",
    "qb": "http://purl.org/linked-data/cube#",
    "rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
    "rdfs": "http://www.w3.org/2000/01/rdf-schema#",
    "sc": "http://schema.org/",
    "schema": "https://schema.org/",
    "sh": "http://www.w3.org/ns/shacl#",
    "skos": "http://www.w3.org/2004/02/skos/core#",
    "sosa": "http://www.w3.org/ns/sosa/",
    "ssn": "http://www.w3.org/ns/ssn/",
    "time": "http://www.w3.org/2006/time#",
    "vann": "http://purl.org/vocab/vann/",
    "void": "http://rdfs.org/ns/void#",
    "wgs": "https://www.w3.org/2003/01/geo/wgs84_pos#",
    "xsd": "http://www.w3.org/2001/XMLSchema#"
  },
  "@id": "https://bio.tools/PASeq",
  "@type": "sc:SoftwareApplication",
  "dcterms:conformsTo": "https://bioschemas.org/profiles/ComputationalTool/0.6-DRAFT",
  "sc:additionalType": "Web application",
  "sc:applicationSubCategory": [
    {
      "@id": "edam:topic_0199"
    },
    {
      "@id": "edam:topic_0781"
    }
  ],
  "sc:citation": "pmcid:PMC6736041",
  "sc:description": "A10 Presence and frequency of M184V mutation in the MOBIDIP trial | AbstractThe MOBIDIP trial evaluated the simplification by protease (PI r) monotherapy for HIV infection versus dual therapy and boosted protease inhibitor plus lamivudine (PI r + 3TC) in controlled patients under second-line regimens. MOBIDIP was interrupted because of a significant number of patients with virological failure (VF) at week 48 (W48) in PI r (33 133, ∼25%) versus in PI r + 3TC (4 132, ∼3%). At the time of first-line VF, 96 per cent of patients harbored the M184V mutation. The presence of the M184V mutation was related to a protective effect against VF in the PI r + 3TC arm. We developed a methodology that allows to determine the frequency of M184V I mutations in the HIV reverse transcriptase (RT) gene in peripheral blood mononuclear cells (PBMC) obtained before MOBIDIP simplification",
  "sc:name": "PASeq",
  "sc:url": "https://www.paseq.org"
}